- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Response to Helicobacter pylori Eradication Triple Therapy in Peptic Ulcer Disease Patients on Curcumin Supplement According to different ABO Phenotypes | ||
| karbala journal of pharmaceutical sciences | ||
| Article 4, Volume 9, Issue 15, 2018, Pages 11-31 PDF (0 K) | ||
| Authors | ||
| Shaymaa Hasan Abbas; Manal Khalid Abdulridha; Akram Ajeel Najeb | ||
| Abstract | ||
| Background: Helicobacter pylori infection is one of the most predominant causes of peptic ulcer disease. There was a correlation between H. pylori infection and ABO phenotypes in peptic ulcer disease patients. Curcumin has anti- H. pylori effect due to its anti-oxidant, antiinflammatory, anti- microbial, and anti-carcinogenic effect. Patients and Methods: This study is a prospective randomized interventional open-label study which designed to show the potential benefit of adjuvant curcumin therapy in peptic ulcer disease Iraqi patients with different ABO phenotypes. The patients were allocated into two groups, group (1) treated with standard triple H. pylori eradication, and group (2) treated with curcumin capsules as adjuvant with the standard triple therapy for two weeks. The ABO phenotypes detected by Anti ABO and Anti-D monoclonal kit and the H. pylori infection was detected at the baseline and after 6 weeks of completion treatment course. Results: highly significant improvement in H. pylori eradication after addition adjuvant curcumin to standard H. pylori eradication triple therapy compared to standard triple therapy alone(P<0.01) for patients holding blood group AB phenotypes ( P<0.01) and significant improvement for patients holding blood group O phenotypes( P<0.05) reach up to (100 %) after 6 weeks from the intervention starting point. Besides, there was improvement in H. pylori eradication for patients holding blood group A and B phenotypes with adjuvant curcumin therapy, though no significant (P>0.05). This study showed no significant difference in BMI among ABO phenotypes (A,B, AB, and O) for both groups 1 and 2 patients after 6 weeks from the intervention starting point(P>0.05).. | ||
| Keywords | ||
| Peptic ulcer disease; Helicobacter pylori infection; Curcumin; Triple therapy | ||
|
Statistics Article View: 845 PDF Download: 219 |
||